MannKind stock climbs after closing treprostinil deal with United Therapeutics

MannKind Corp. (NASDAQ:MNKD; Tel Aviv:MNKD) shot up $0.98 (89%) to $2.08. on Sept. 4 after signing a deal with United Therapeutics Corp. (NASDAQ:UTHR) for

Read the full 248 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE